Flow Cytometry Indicates Treatment Response in AML For children with acute myeloid leukemia (AML), minimal residual disease (MRD) activity, as measured using flow cytometry, is a good indicator of ...

1, 2 Recent developments in flow cytometry ... plot (Figure 2). The lineage-restricted antigens CD19, CD79a, CD22 for BCP-ALL; CD3, CD5, CD7 for T-ALL and CD13, CD33, MPO for AML displayed a ...

In acute myeloid leukemia (AML), MRD is typically assessed by using flow cytometry and, at some centers, by quantifying NPM1 transcripts — an independent and powerful prognosticator of AML.

Six-parameter, four-color flow cytometry was performed with a FACSCalibur ... on all cell populations defined in the CD45/SSC dot-plot. Gating strategy to identify erythroid precursors was based ...

A new liquid biopsy test that uses flow cytometry to detect cancer cells has been FDA approved for chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome ...

for the development of a flow cytometry method for the detection and quantification of human Equilibrative Nucleoside Transporter (hENT1) in patients suffering from Acute Myeloid Leukaemia (AML). The ...

in elderly patients with Acute Myeloid Leukemia (AML). SCNP is a multiparametric flow cytometry-based platform that provides robust, human cell-based translational models of disease, drug activity ...